Contact Us |
Centers for Medicare & Medicaid Services (CMS) has expanded coverage to HCT for MDS, Sickle Cell Disease, Myelofibrosis, and Multiple Myeloma under Coverage with Evidence Development (CED). This means transplants for these indications need to take place within a CMS-approved clinical study that meets federal guidelines.
We are facilitating national clinical studies for each indication that you can enroll your patients in to meet the CED requirements.
MDS CED (10-CMS-MDS) - open for enrollment
Multiple Myeloma CED (17-CMS-MM) - open for enrollment
Myelofibrosis CED (16-CMS-MF) - open for enrollment
Sickle Cell Disease CED (BMT CTN 1503) - open for enrollment
Sickle Cell Disease CED (17-CMS-SCD) - open for enrollment